THX Pharma Stock Deutsche Boerse AG

3VG

FR0013286259

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 02:02:28 2026-09-10 EDT			5-day change	1st Jan Change
3.385 ^EUR	-3.01%		-16.11%	+69.25%

09-02	THX Pharma Partnership Seeks Regulatory Clearance for Late-stage Juvenile Batten Disease Drug Trial	MT
09-01	THX Pharma Submits Regulatory Applications To Initiate Phase 3 Clinical Trial Of Batten-1 In Juvenile Batten Disease	CI

News in other languages : THX Pharma

09-09	THX Pharma et la BBDF obtiennent un brevet
09-09	Bourse : Inditex (Zara) publie, Apple plie, Airbus engrange
09-09	Thx Pharma : Rectificatif : THX Pharma et la Beyond Batten Disease Foundation annoncent la délivrance d’un brevet européen protégeant l’utilisation de Batten-1 dans la maladie de Batten juvénile (CLN3)
09-09	Le baril joue à touche-touche avec les 100 dollars
09-08	Thx Pharma : THX Pharma et la Beyond Batten Disease Foundation annoncent la délivrance d’un brevet européen protégeant l’utilisation de Batten-1 dans la maladie de Batten juvénile (CLN3)

More news

Managers and Directors : THX Pharma

Manager	Title	Age	Since
Mathieu Bernard Mari Charveriat CEO	Chief Executive Officer	-	2022-12-31
Christine Placet DFI	Director of Finance/CFO	-	2024-03-31
Marie Sebille CTO	Chief Tech/Sci/R&D Officer	-	2021-10-18

Director	Title	Age	Since
Franck Joseph Mouthon BRD	Director/Board Member	-	2024-03-30
Mathieu Bernard Mari Charveriat CHM	Chairman	-	2024-03-30
Julien Veys BRD	Director/Board Member	-	-

More insiders

THX Pharma (formerly Theranexus) is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. THX Pharma has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-28 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change
26-09-10	€3.385	-3.01%
26-09-09	€3.490	-6.43%
26-09-08	€3.730	+1.08%
26-09-07	€3.690	-1.47%
26-09-04	€3.745	-7.19%

Delayed Quote Deutsche Boerse AG

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.380EUR

Average target price

5.800EUR

Spread / Average Target

+71.60%

Consensus

Annual profits - Rate of surprise

Company calendar

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Market Cap	46.63M 54.22M 44M 40.08M 74.93M 5.18B 75.61M 524M 202M 2.63B 204M 199M 8.35B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	22.93M 26.67M 21.64M 19.71M 36.85M 2.55B 37.18M 258M 99.18M 1.29B 100M 97.95M 4.11B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	91.97%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALTHX	Real-time
CBOE		Real-time
Börse Stuttgart	3VG	Delayed
Deutsche Boerse AG	3VG	Delayed
Boerse Muenchen	3VG	Real-time
CBOE		Real-time

09-02	THX Pharma Partnership Seeks Regulatory Clearance for Late-stage Juvenile Batten Disease Drug Trial	MT
09-01	THX Pharma Submits Regulatory Applications To Initiate Phase 3 Clinical Trial Of Batten-1 In Juvenile Batten Disease	CI
07-09	THX Pharma secures its financial roadmap
06-23	THX Pharma appoints Sophie Jacq Lapointe to its board of directors
06-22	THX Pharma Announces Appointment of Sophie Jacq Lapointe to Board of Directors	CI
06-10	THX Pharma, Exeltis Receive Positive EU Opinion for TX01 Pediatric Investigation Plan	MT
06-09	THX Pharma And Exeltis Secure EMA Approval Of The Paediatric Investigation Plan For TX01 Unlocking The PUMA Registration Pathway	CI
06-09	EMA grants pediatric green light for THX Pharma's TX01
05-15	Certain Shares of THX Pharma Société Anonyme are subject to a Lock-Up Agreement Ending on 16-MAY-2026.	CI
04-28	THX Pharma Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-20	Air Liquide, Danone, Parrot... Key Stocks to Watch Today in Paris
02-19	Imerys, GTT, Louis Hachette Group... Key Stocks to Watch Tomorrow in Paris
02-19	THX Pharma Reveals Its Cash Position

09-09	Thx Pharma : Corrected press release : THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)	AT
09-08	Thx Pharma : THX Pharma and the Beyond Batten Disease Foundation Announce the Grant of a European Patent Protecting the Use of Batten-1 in Juvenile Batten Disease (CLN3)	AT
09-01	Thx Pharma : THX Pharma, BBDF and Biocodex Announce Regulatory Submissions for the Phase 3 Clinical Trial of Batten-1 in Juvenile Batten Disease (CLN3)	AT
07-09	Thx Pharma : THX Pharma Reports Cash Position as of June 30, 2026	AT
06-23	Thx Pharma : THX Pharma Announces the Appointment of Sophie Jacq Lapointe to its Board of Directors	AT

1 day	-3.01%
1 week	-16.11%
Current month	-17.94%
1 month	-24.53%
3 months	+8.32%
6 months	+5.45%
Current year	+69.25%

THX Pharma Stock Deutsche Boerse AG

Stocks

3VG

FR0013286259

Biotechnology & Medical Research

Valuation : THX Pharma

Chart: THX Pharma

Latest news : THX Pharma

Press Releases : THX Pharma

News in other languages : THX Pharma

Quotes and Performance

Price Extremes

Managers and Directors : THX Pharma

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	3.38	3.87
1 month	3.38	4.4
Current year	1.84	4.49
1 year	1.51	4.49
3 years	0.36	4.49
5 years	0.36	9.02
10 years	0.36	21.5

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THX PHARMA	-3.01%	-16.11%	-	-	55.8M
WUXI APPTEC CO., LTD.	-0.25%	-1.36%	+44.08%	+102.76%	68.52B
ARGENX SE	-1.09%	-6.20%	+30.50%	+76.56%	62.88B
INSMED INCORPORATED	-1.18%	+0.47%	-12.78%	+384.69%	28.13B
WUXI BIOLOGICS (CAYMAN) INC.	-1.39%	-4.76%	+30.11%	+9.70%	25.56B
BIONTECH SE	-1.76%	-6.30%	-4.55%	-19.75%	24.65B
GENMAB A/S	-2.39%	-5.19%	+17.75%	-20.95%	19.81B
PHARMAESSENTIA CORPORATION	-1.86%	-2.22%	+202.03%	+353.89%	17.69B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.32%	-5.52%	-5.86%	+492.06%	14.66B
EXELIXIS, INC.	-1.54%	-2.88%	+52.33%	+159.75%	14.45B
Average	-1.70%	-2.00%	+39.29%	+170.97%	30.71B
Weighted average by Cap.	-1.22%	-2.18%	+35.58%	+136.80%

	2026 *	2027 *
Net sales	-	-
Net income	11.9M 13.84M 11.23M 10.23M 19.12M 1.32B 19.29M 134M 51.46M 671M 51.96M 50.83M 2.13B	4.3M 5M 4.06M 3.7M 6.91M 478M 6.97M 48.32M 18.6M 242M 18.78M 18.37M 770M
Net Debt	-23.7M -27.56M -22.36M -20.37M -38.08M -2.63B -38.43M -266M -102M -1.34B -103M -101M -4.24B	-27.4M -31.86M -25.85M -23.55M -44.03M -3.05B -44.43M -308M -118M -1.55B -120M -117M -4.91B